THE ROLE OF AMPK AND MTOR IN THE DEVELOPMENT OF INSULIN RESISTANCE AND TYPE 2 DIABETES. THE MECHANISM OF METFORMIN ACTION (literature review)

Authors

  • Pushkarev V. M. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv
  • Sokolova L. K. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv
  • Pushkarev V. V. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv
  • Tronko M. D. SI «V. P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kyiv

DOI:

https://doi.org/10.21856/j-PEP.2016.3.09

Keywords:

type 2 diabetes, insulin-resistance, obesity, inflammation, metformin

Abstract

It was analyzed the cellular and molecular links between chronic low-grade inflammation and caused by inflammation insulin resistance and type 2 diabetes. Particular emphasis is placed on the participation of AMPK and mTORC1 in the development of metabolic diseases caused by obesity. A detailed analysis of the biochemical mechanisms of action of the main drug used in the treatment of insulin resistance and type 2 diabetes — metformin.

References

Odegaard JI, Chawla A. Science 2013; 339(6116):172-177.

Ortega-Gómez A, Perretti M, Soehnlein O. EMBO Mol Med 2013; 5(5):661-674.

Aprile-Garcia F, Antunica-Noguerol M, Budziñski ML, et al. Endocr Connect 2014; 3:R1-R12.

Ghosh S. Handbook of transcription factor NF-kappaB, LLC Boca Raton, 2007: 223 p.

Hayden MS, Ghosh S. Genes Dev 2012; 26:203-234.

Blaylock RL. Surg Neurol Int 2015; 6(92):1-25.

Medzhitov R. Nature 2008; 454(7203):428-435.

Harris RE, Casto BC, Harris ZM. World J Clin Oncol 2014; 5(4):677-692.

Koh TJ, DiPietro LA. Expert Rev Mol Med 2011; 13:e23.

Dennis EA, Norris PC. Nat Rev Immunol 2015; 15(8):511-523.

Knab LM, Grippo PJ, Bentrem DJ. World J Gastroenterol 2014; 20(31):10729-10739.

Kapadia R, Yi JH, Vemuganti R. Front Biosci 2008; 13:1813-1826.

Ye J. Front Med 2013; 7(1):14-24.

O’Rourke RW. Surg Obes Relat Dis 2014; 10(6):1208-1219.

Fenton JI, Hord NG, Lavigne JA, et al. Cancer Epidemiol Biomarkers Prev 2005; 14:1646-1652.

Lipina C, Irving AJ, Hundal HS. Am J Physiol Endocrinol Metab 2014; 307:E1-E13.

Ritov VB, Menshikova EV, Azuma K, et al. Am J Physiol Endocrinol Metab 2010; 298:E49-E58.

Lipina C, Macrae K, Suhm T, et al. Diabetes 2013; 62:3426-3436.

Ruderman NB, Carling D, Prentki M, Cacicedo JM. J Clin Invest 2013; 123(7):2764-2772.

Xiao B, Sanders MJ, Underwood E, et al. Nature 2011; 472(7342):230-233.

Oakhill JS, Steel R, Chen ZP, et al. Science 2011; 332(6036):1433-1435.

Racioppi L, Means AR. J Biol Chem 2012; 287(38):31658-31665.

Jeong KJ, Kim GW, Chung SH. J Ginseng Res 2014; 38:83-88.

Li Y, Xu S, Mihaylova MM, et al. Cell Metab 2011; 13:376-388.

Steinberg GR, Schertzer JD. Immunol Cell Biol 2014; 92:340-345;

Hardie DG, Ross FA, Hawley SA. Chem Biol 2012; 19:1222-1236.

Galic S, Fullerton MD, Schertzer JD, et al. J Clin Investig 2011; 121:4903-4915.

Ruderman NB, Xu XJ, Nelson L, et al. Am J Physiol Endocrinol Metab 2010; 298(4):E751-E760.

Price NL, Gomes AP, Ling AJ, et al. Cell Metab 2012; 15(5):675-690.

Kim YC, Guan KL. Clin Invest 2015; 125(1):25-32.

Covarrubias AJ, Aksoylar HI, Horng T. Semin Immunol 2015; 27(4):286-296.

Blagosklonny MV. Cell Death Dis 2013; 4:e964.

Zoncu R, Efeyan A, Sabatini DM. Nat Rev Mol Cell Biol 2011; 12:21-35.

Tchkonia T, Zhu Y, van Deursen J, et al. J Clin Invest 2013; 123:966-972.

Ueno M, Carvalheira JB, Tambascia RC, et al. Diabetologia 2005; 48:506-518.

Saha AK, Xu XJ, Balon TW, et al. Cell Cycle 2011; 10(20):3447-3451.

Yu Y, Yoon SO, Poulogiannis G, et al. Science 2011; 332:1322-1326.

Leontieva OV, Demidenko ZN, Blagosklonny MV. Cell Death Dis 2014; 5: e1214.

Gunasekaran U, Gannon M. Aging (Albany NY) 2011; 3:565-575.

An H, He L. J Endocrinol 2016; 228(3):R97-R106.

Meng S, Cao J, He Q, et al. J Biol Chem 2015; 290:3793-3802.

Foretz M, Hebrard S, Leclerc J, et al. J Clin Invest 2010; 120:2355-2369.

Ouyang JY, Parakhia RA, Ochs RS. J Biol Chem 2011; 286:1-11.

Miller RA, Chu QW, Xie JX, et al. Nature 2013; 494:256-260.

Madiraju AK, Erion DM, Rahimi Y, et al. Nature 2014; 510:542-546.

Hur KY, Lee M-S. J Diab Invest 2015; 6:600-609.

Kim KH, Jeong YT, Kim SH, et al. Biochem Biophys Res Commun 2013; 440:76-81.

Duca FA, Cote CD, Rasmussen BA, et al. Nature Med 2015; 21:506-511.

Laugerette F, Vors C, Geloen A, et al. J Nutr Biochem 2011; 22:53-59.

Elamin EE, Masclee AA, Dekker J, et al. J Nutr 2013; 143:1872-1881.

Arkan MC, Hevener AL, Greten FR, et al. Nature Med 2005; 11:191-198.

Gao ZG, Yin J, Zhang J, et al. J Biol Chem 2009; 284:18368-18376.

Huang NL, Chiang SH, Hsueh CH, et al. Int J Cardiol 2009; 134:169-175.

Lee SK, Lee JO, Kim JH, et al. J Cell Biochem 2011; 112:1259-1267.

Maida A, Lamont BJ, Drucker DJ. Diabetologia 2011; 54:339-349.

Kim MH, Jee JH, Park S, et al. J Endocrinol 2014; 220:117-128.

Kim J, Kim YC, Fang C, et al. Cell 2013; 152:290-303.

Mizushima N, Komatsu M. Cell 2011; 147:728-741.

Kim J, Cheon H, Jeong YT, et al. J Clin Invest 2014; 124:3311-3324.

Lim YM, Lim H, Hur KY, et al. Nat Commun 2014; 5:4934.

Jiang Y, Huang W, Wang J, et al. Int J Biochem Cell Biol 2014; 10:268-277.

He C, Zhu H, Li H, et al. Diabetes 2013; 62:1270-1281.

Song YM, Lee YH, Kim JW, et al. Autophagy 2015; 11(1):46-59.

Lee HM, Kim JJ, Kim HJ, et al. Diabetes 2013; 62:194-204.

Zhou R, Tardivel A, Thorens B, et al. Nat Immunol 2010; 11:136-140.

Chai TF, Hong SY, He H, et al. Cell Signal 2012; 24:1700-1705.

Bodmer M, Meier C, Krähenbühl S, et al. Diabetes Care 2008; 31: 2086-2091.

Stades AM, Heikens JT, Erkelens DW, et al. J Intern Med 2004; 255:179-187.

FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. FDA’s website.

Novelle MG, Ali A, Dieguez C, et al. Cold Spring Harb Perspect Med 2016; 6: a025932.

Downloads

Published

2021-08-17

How to Cite

Pushkarev, V. M., Sokolova, L. K., Pushkarev, V. V., & Tronko, M. D. (2021). THE ROLE OF AMPK AND MTOR IN THE DEVELOPMENT OF INSULIN RESISTANCE AND TYPE 2 DIABETES. THE MECHANISM OF METFORMIN ACTION (literature review). Problems of Endocrine Pathology, 57(3), 77-90. https://doi.org/10.21856/j-PEP.2016.3.09

Most read articles by the same author(s)